Ethyl Acetate → 9-(2-Bromoacetyl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione
反応式
C([O:3][C:4]([C:6]1[CH:15]=[CH:14][CH:13]=[C:12]2[C:7]=1[CH2:8][CH2:9][N:10]1[C:20](=[O:21])[CH2:19][NH:18][C:17](=[O:22])[CH:16]=[C:11]12)=[CH2:5])C.C1C(=O)N([Br:30])C(=O)C1.CCOC(C)=O>C1COCC1.O.[Cl-].[Na+].O>[Br:30][CH2:3][C:4]([C:6]1[CH:15]=[CH:14][CH:13]=[C:12]2[C:7]=1[CH2:8][CH2:9][N:10]1[C:20](=[O:21])[CH2:19][NH:18][C:17](=[O:22])[CH:16]=[C:11]12)=[O:5]参加物
6
反応物 3
生成物 1
試薬・触媒・溶媒 2
反応条件
- 温度
- 0 °C
実験手順
111-2. A solution of 9-(1-ethoxyvinyl)-3,4,7,8-tetrahydro -[1,4]diazepino[7,1-a]isoquinoline-2,5-dione (1.2 g, 4.02 mmol) in a mixture of THF/H2O (3:1, 40 mL) was treated with NBS (716 mg, 4.02 mmol) and the mixture was stirred at 0° C. for 10 min. The mixture was partioned between AcOEt and brine and the org. phase was separated, dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (880 mg) that was used as it is in the next step. UPLC-MS: MS 349.0 (M+H+); UPLC rt 0.69 min.
後処理
- customphase was separated
- dry with materialdried over Na2SO4
- filtrationfiltered
- concentrationconcentrated in vacuo
出典と根拠
- ORDレコード
- ord-7c0cca5adc6f4c21b17a4e11f53e9e23
- 出典データセット
- uspto-grants-2016_03
- 特許番号
- US09284331B2
反応ノート
読み込み中…